Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 8/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.37 |
| ▸ | PRKDC | P78527 | 3/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562932 | 1.00 | ENPP1 (0.49) | ENPP1SIRT2SIRT1SIRT3PTGS1 | |
| SCHEMBL25552391 | 0.90 | ENPP1 (0.47) | ENPP1SIRT2SIRT1SIRT3PTGS1 | |
| SCHEMBL21664292 | 0.90 | ENPP1 (0.48) | ENPP1SIRT2SIRT1SIRT3PTGS1 | |
| SCHEMBL21664410 | 0.88 | ENPP1 (0.59) | ENPP1PDE10APDE3A | |
| SCHEMBL25551951 | 0.87 | ENPP1 (0.52) | ENPP1SIRT2SIRT1SIRT3PDE10A | |
| SCHEMBL21664412 | 0.87 | ENPP1 (0.45) | ENPP1SIRT2SIRT1SIRT3PTGS1 | |
| SCHEMBL26554795 | 0.85 | ENPP1 (0.41) | ENPP1PTGS1PTGS2PDE10APRKDC | |
| SCHEMBL21664290 | 0.84 | ENPP1 (0.52) | ENPP1SIRT2SIRT1SIRT3PRKDC | |
| SCHEMBL21664248 | 0.83 | PRKDC (0.47) | ENPP1PTGS1PTGS2PDE10APRKDC | |
| SCHEMBL21664272 | 0.83 | ENPP1 (0.47) | ENPP1PTGS1PTGS2PDE10APRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551188-B1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RES INST (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| US-11524010-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210369713-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2021-12-02 | — | — | US | disclosed |
| US-20200038402-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038402-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXN2, TXNRD1 | ENPP1 2457/4885SIRT2 1152/4885SIRT1 444/4885 |
| US-11524010-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
| US-20210369713-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885SIRT2 741/4885SIRT1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.